Sesen Bio, Inc. (SESN): Price and Financial Metrics


Sesen Bio, Inc. (SESN)

Today's Latest Price: $1.33 USD

0.07 (5.16%)

Updated Dec 3 11:30am

Add SESN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

SESN Stock Price Chart Interactive Chart >

Price chart for SESN

SESN Price/Volume Stats

Current price $1.33 52-week high $1.54
Prev. close $1.26 52-week low $0.37
Day low $1.27 Volume 1,279,721
Day high $1.36 Avg. volume 1,478,789
50-day MA $1.18 Dividend yield N/A
200-day MA $0.89 Market Cap 171.38M

Sesen Bio, Inc. (SESN) Company Bio


Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.


SESN Latest News Stream


Event/Time News Detail
Loading, please wait...

SESN Latest Social Stream


Loading social stream, please wait...

View Full SESN Social Stream

Latest SESN News From Around the Web

Below are the latest news stories about Sesen Bio Inc that investors may wish to consider to help them evaluate SESN as an investment opportunity.

Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H. C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020. Event: H. C. Wainwright 22nd Annual Global Investment Conference Date: September 15, 2020 Time: 10:30 - 10:50 AM ET A live webcast of the Company’s presentation

Business Wire | September 8, 2020

Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020. The Company will provide an update on the regulatory process in the US and Europe, and the BD process outside the US. Event: Canaccord Genuity 40th Annual

Business Wire | August 5, 2020

Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company in China specializing in the manufacturing and marketing of active pharmaceutical ingredients and drug products, today announced that the companies have entered into an exclusive licensing agreement for the manufacture, development and c

Business Wire | July 31, 2020

Sesen Bio to Host Conference Call to Provide OUS Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31, 2020 at 8:00 a.m. EDT to provide an Outside the US (“OUS”) and general business update. To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to confe

Business Wire | July 30, 2020

Edited Transcript of SESN earnings conference call or presentation 11-May-20 12:00pm GMT

Q1 2020 Sesen Bio Inc Earnings Call

Yahoo | June 12, 2020

Read More 'SESN' Stories Here

SESN Price Returns

1-mo 31.68%
3-mo 33.08%
6-mo 69.75%
1-year 10.83%
3-year 104.62%
5-year -55.22%
YTD 27.88%
2019 -26.76%
2018 75.09%
2017 -57.54%
2016 -36.54%
2015 -74.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0154 seconds.